Literature DB >> 21857525

Diabetes mellitus and increased risk of cholangiocarcinoma: a meta-analysis.

Wei Jing1, Gang Jin, Xuyu Zhou, Yingqi Zhou, Yijie Zhang, Chenghao Shao, Rui Liu, Xiangui Hu.   

Abstract

Diabetes mellitus (DM) has been reported to be associated with an increased risk of several types of cancers. However, its relationship with cholangiocarcinoma (CC), which includes intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC), remains unclear. We conducted a meta-analysis to assess the association between diabetes and the risk of CC (including ICC and ECC). We identified studies by a literature search of Medline (from 1 January 1966) and Embase (from 1 January 1974), through 30 November 2010, and by searching the reference lists of pertinent articles. Summary relative risks (RRs) with corresponding 95% confidence intervals (CIs) were calculated with a random-effects model. A total of 15 articles (10 case-control and five cohort studies) were included in this study. The number of reports on DM and risk of specific cancer were as follows: CC (n=5), ECC (n=9), and ICC (n=9). Compared with those without diabetes, individuals with diabetes had an increased risk of CC (summary RRs, 1.60; 95% CI, 1.38-1.87; P=0.992 for heterogeneity), ECC (summary RRs, 1.63; 95% CIs, 1.29-2.05; P=0.005 for heterogeneity), and ICC (summary RRs, 1.97; 95% CIs, 1.57-2.46; P=0.025 for heterogeneity). The funnel plot revealed no evidence for publication bias concerning diabetes and the risk of CC (including ICC and ECC). These findings strongly support the positive link between DM and the increased risk of CC (including ICC and ECC).

Entities:  

Mesh:

Year:  2012        PMID: 21857525     DOI: 10.1097/CEJ.0b013e3283481d89

Source DB:  PubMed          Journal:  Eur J Cancer Prev        ISSN: 0959-8278            Impact factor:   2.497


  32 in total

1.  Association between type 2 diabetes and risk of cancer mortality: a pooled analysis of over 771,000 individuals in the Asia Cohort Consortium.

Authors:  Yu Chen; Fen Wu; Eiko Saito; Yingsong Lin; Minkyo Song; Hung N Luu; Prakash C Gupta; Norie Sawada; Akiko Tamakoshi; Xiao-Ou Shu; Woon-Puay Koh; Yong-Bing Xiang; Yasutake Tomata; Kemmyo Sugiyama; Sue K Park; Keitaro Matsuo; Chisato Nagata; Yumi Sugawara; You-Lin Qiao; San-Lin You; Renwei Wang; Myung-Hee Shin; Wen-Harn Pan; Mangesh S Pednekar; Shoichiro Tsugane; Hui Cai; Jian-Min Yuan; Yu-Tang Gao; Ichiro Tsuji; Seiki Kanemura; Hidemi Ito; Keiko Wada; Yoon-Ok Ahn; Keun-Young Yoo; Habibul Ahsan; Kee Seng Chia; Paolo Boffetta; Wei Zheng; Manami Inoue; Daehee Kang; John D Potter
Journal:  Diabetologia       Date:  2017-03-07       Impact factor: 10.122

Review 2.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

3.  CA 19-9 as a Marker of Survival and a Predictor of Metastization in Cholangiocarcinoma.

Authors:  Rosa Coelho; Marco Silva; Eduardo Rodrigues-Pinto; Hélder Cardoso; Susana Lopes; Pedro Pereira; Filipe Vilas-Boas; João Santos-Antunes; José Costa-Maia; Guilherme Macedo
Journal:  GE Port J Gastroenterol       Date:  2017-02-23

Review 4.  Preneoplastic conditions underlying bile duct cancer.

Authors:  Lena Sibulesky; Justin Nguyen; Tushar Patel
Journal:  Langenbecks Arch Surg       Date:  2012-03-06       Impact factor: 3.445

5.  Hepatitis B virus infection, diabetes mellitus, and their synergism for cholangiocarcinoma development: a case-control study in Korea.

Authors:  Ban Seok Lee; Eun-Cheol Park; Seung Woo Park; Chung Mo Nam; Jaehoon Roh
Journal:  World J Gastroenterol       Date:  2015-01-14       Impact factor: 5.742

6.  Outcomes of Hepatic Resection in Intrahepatic Cholangiocarcinoma Patients with Diabetes, Hypertension, and Dyslipidemia: Significance of Routine Follow-Up.

Authors:  Takayoshi Nishioka; Shoji Kubo; Shogo Tanaka; Kenichi Wakasa; Shigekazu Takemura; Masahiko Kinoshita; Genya Hamano; Yuko Kuwae; Toshihiko Shibata; Shigefumi Suehiro
Journal:  Liver Cancer       Date:  2016-03-17       Impact factor: 11.740

7.  Aspirin may prevent cholangiocarcinoma: a case-control study from the United kingdom.

Authors:  N E Burr; R J Talboys; S Savva; A Clark; M Phillips; M Metcalfe; A Dennison; R Robinson; M P Lewis; M Rhodes; S Rushbrook; A R Hart
Journal:  Dig Dis Sci       Date:  2014-02-18       Impact factor: 3.199

Review 8.  Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic.

Authors:  Massimiliano Cadamuro; Alberto Lasagni; Angela Lamarca; Laura Fouassier; Maria Guido; Samantha Sarcognato; Enrico Gringeri; Umberto Cillo; Mario Strazzabosco; Jose Jg Marin; Jesus M Banales; Luca Fabris
Journal:  Expert Opin Investig Drugs       Date:  2021-02-23       Impact factor: 6.206

Review 9.  Liquid biopsy in cholangiocarcinoma: Current status and future perspectives.

Authors:  Gianluca Rompianesi; Marcello Di Martino; Alex Gordon-Weeks; Roberto Montalti; Roberto Troisi
Journal:  World J Gastrointest Oncol       Date:  2021-05-15

10.  Metabolic syndrome, obesity, and gastrointestinal cancer.

Authors:  Shintaro Fujihara; Hirohito Mori; Hideki Kobara; Noriko Nishiyama; Mitsuyoshi Kobayashi; Makoto Oryu; Tsutomu Masaki
Journal:  Gastroenterol Res Pract       Date:  2012-12-11       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.